Neuro-oncology · 2015
CNS Anticancer Drug Discovery and Development Conference White Paper.
Conference ProceedingsПоддержка исследования: вне правительства СШАConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Levin Victor A, Tonge Peter J, Gallo James M, Birtwistle Marc R, Dar Arvin C, Iavarone Antonio, Paddison Patrick J, Heffron Timothy P, Elmquist William F, Lachowicz Jean E, Johnson Ted W, White Forest M, Sul Joohee, Smith Quentin R, Shen Wang, Sarkaria Jann N, Samala Ramakrishna, Wen Patrick Y, Berry Donald A, Petter Russell C
Аннотация
Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.